Xilio Therapeutics (formerly Akrevia Therapeutics) is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics. It applies its proprietary technology that enables to increase therapeutic activity specifically within the tumor while reducing toxicity throughout the body. The product candidates include XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody, and XTX202, an interleukin 2 therapy.